Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.46 USD
Change Today +0.37 / 5.22%
Volume 3.1M
As of 3:39 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ACHN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/22/14 - $16.87
52 Week Low
08/24/15 - $6.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

achillion pharmaceuticals (ACHN) Related Businessweek News

No Related Businessweek News Found

achillion pharmaceuticals (ACHN) Details

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise ACH-3102, a NS5A inhibitor, which completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor that is in Phase I clinical development; and Sovaprevir, a NS3 protease inhibitor, which completed Phase II clinical trial. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally; and license and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize the company’s hepatitis C virus assets. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

67 Employees
Last Reported Date: 03/5/15
Founded in 1998

achillion pharmaceuticals (ACHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $484.1K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $347.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $457.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $335.4K
Compensation as of Fiscal Year 2014.

achillion pharmaceuticals (ACHN) Key Developments

Achillion Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2015

Achillion Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported a net loss of $29.0 million or $0.25 per share, compared with a net loss of $15.7 million or $0.16 per share for the second quarter of 2014. Revenue was $711,000. Loss from operations was $29,188,000 compared to $15,766,000 a year ago. For the six months ended June 30, 2015, the company reported a net loss of $48.2 million, compared to a net loss of $31.7 million in the same period in 2014. The company recognized $711,000 in revenue during the six months ended June 30, 2015 representing a portion of the premium paid by JJDC associated with its equity purchase of the company’s common stock. Revenues were $711,000. Loss from operations was $48,587,000 compared to $32,001,000 a year ago. Basic and diluted net loss per share was $0.42 compared to $0.33 a year ago. The Company expects total annual revenue to be $66 million. The company expects that research and development expenses during 2015 will be approximately $60 million to $65 million, compared to previously provided guidance of $85 million to $95 million, and that general and administrative expenses will add $20 million to $25 million of expense with an annual net loss anticipated of $18 million to $20 million. Net cash used in operating activities in 2015 will be approximately $65 to $70 million, based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs, as compared to previous guidance of $100 million to $110 million. The net loss per share is anticipated to be approximately $0.15 per share.

Achillion Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 10, 2015

Achillion Pharmaceuticals, Inc. announced that they will report Q2, 2015 results on Aug 10, 2015

Achillion Pharmaceuticals, Inc. Presents at UBS SMID Cap One-on-One Conference, Aug-04-2015

Achillion Pharmaceuticals, Inc. Presents at UBS SMID Cap One-on-One Conference, Aug-04-2015 . Venue: Boston Harbor Hotel, 70 Rowes Wharf, Boston, MA 02110, United States. Speakers: Glenn Schulman, Senior Director, IR, Mary Kay Fenton, Chief Financial Officer, Executive Vice President and Secretary, Milind S. Deshpande, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $7.46 USD +0.37

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,117 GBp +83.50
Bavarian Nordic A/S kr286.50 DKK -6.00
Chimerix Inc $50.45 USD +2.91
Emergent BioSolutions Inc $33.05 USD +0.38
PharmAthene Inc $1.46 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,224.1x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,071.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at